Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GFER | P55789 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PDE9A | O76083 | 1/20 | 0.35 |
| ▸ | PDE1A | P54750 | 1/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | PNP | P00491 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6371836 | 0.84 | PDE9A (0.41) | MAPTGFERKDM4ELMNAGAA | |
| SCHEMBL6368258 | 0.82 | KDM4E (0.37) | MAPTGFERKDM4ELMNAGAA | |
| SCHEMBL6366910 | 0.78 | PDGFRB (0.38) | MAPTGFERKDM4ELMNAGAA | |
| SCHEMBL6371909 | 0.72 | HSP90AA1 (0.46) | MAPTKDM4EMAPK1PDE9APDE1A | |
| SCHEMBL3492113 | 0.70 | PDE5A (0.59) | PDE9APDE1APDE1BPDE1CPNP | |
| SCHEMBL6366909 | 0.69 | HSP90AA1 (0.43) | KDM4EGAAALDH1A1PDE9AHSP90AA1 | |
| SCHEMBL6374085 | 0.68 | PDE9A (0.56) | LMNAGAAMAPK1ALDH1A1PDE9A | |
| SCHEMBL6367437 | 0.67 | PDE9A (0.49) | MAPTLMNAMAPK1PDE9APDE1A | |
| SCHEMBL3491632 | 0.66 | MAPT (0.53) | MAPTKDM4EGAAMAPK1RNASEH1 | |
| SCHEMBL3494602 | 0.66 | AR (0.48) | PDE9APDE1APDE1BPDE1CPNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967204-B2 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | MAPT 4748/4885GFER 4370/4885KDM4E 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.